PRESS RELEASE

MicThera Raises €4.75 Million Seed Round Co-Led by Indaco Venture Partners and LIFE BioCEEd to Advance First-in-Class Biologic for Advanced Prostate Cancer

Milan, 24 November 2026 – MicThera, a pre-clinical oncology biotech company, today announced that it has raised €4.75 million in a Seed round co-led by life sciences specialist investors Indaco Venture Partners SGR S.p.a. and LIFE BioCEEd a.s., with participation from private investors. Indaco, which first backed MicThera in its 2024 pre-seed round, also invests through Indaco Bio Parallel Lombardia Fund backed by «Lombardia Venture STEP» of Regione Lombardia, financed by RP ERDF 2021-2027 (Action 1.6.2) and managed by Finlombarda.

Proceeds will fund:

- MicThera's lead programme, through Clinical Candidate Nomination and IND-enabling studies;
- Further development of the company's discovery platform for identifying new drug candidates in metagenomic data.

The financing will enable MicThera to advance its lead programme towards clinical development, addressing a significant unmet medical need in metastatic prostate cancer. Patients whose disease progresses despite hormone-based treatments and newer PSMA-targeted therapies face limited treatment options, highlighting the need for new therapeutic approaches.

MicThera's lead programme, PV048, is a first-in-class biologic being developed to address this unmet need, with the potential to offer a new therapeutic approach for patients with advanced prostate cancer who have exhausted existing treatment options.

"Patients with metastatic prostate cancer whose disease progresses despite AR- and PSMA-targeted therapies have very few options left," said **Nicolò Pernigoni, PhD, CEO and co-founder of MicThera**. *"Our molecule has demonstrated strong activity in treatment-resistant models and superior properties compared to drugs tested in phase 2 clinical trials. This financing gives us what we need to reach clinical candidate nomination and to begin the work that will bring our molecule to patients. We are grateful to Indaco for backing us again, and we welcome LIFE BioCEEd, whose company-building experience in early-stage life sciences adds a valuable international perspective."*

"As investors since MicThera's inception, we are proud to have accompanied the company in its growth up to this new round that confirms the strength of the science and team. We look forward to supporting MicThera through the next phase of its journey alongside the investors that have joined us in this round" said **Goncalo Rebelo de Andrade, Partner of the Indaco BIO Fund , managed by Indaco Venture Partners SGR**.

"MicThera brings together compelling science, an experienced team and a clear focus on patients with limited treatment options. This investment reflects our commitment to helping translate promising research into therapies. We look forward to working with the team and our fellow investors to advance PV048 towards clinical development" said **Stefan Savić, CEO of LIFE BioCEEd**, who joins MicThera's Board of Directors.

New Board of Directors. Following the financing, Nicolò Pernigoni was reconfirmed as CEO and Board member, and Dr. Gonçalo Rebelo de Andrade was reconfirmed as Chairman. They are joined by Elena Beltrami, expert in clinical pharmacology, representing Indaco Venture Partners, by Stefan Savić representing LIFE BioCEEd, and by Prof. Andrea Alimonti, representing the Founders.

COESIONE ITALIA 21-27 LOMBARDIA | Cofinanziato dall'Unione europea | Regione Lombardia

About MicThera

MicThera S.r.l. Società Benefit is a preclinical-stage biotech company developing first-in-class therapies for hard-to-treat cancers. Founded in 2023 by Dr. Nicolò Pernigoni, Prof. Andrea Alimonti, and Prof. Arianna Calcinotto as a spin-off of the Institute of Oncology Research (IOR, Bellinzona), MicThera is headquartered in Lodi Vecchio (Lombardy, Italy) and has a Swiss subsidiary in Bellinzona. The company maintains strong collaboration with world-renowned research institutions and academic centers. www.micthera.com

About Indaco Venture Partners

Indaco Venture Partners SGR is one of the largest independent Italian venture capital asset manager, with eight funds totaling more than €390 million. Its life sciences fund, Indaco Bio, invests in innovative drug therapies, with a particular focus on oncology, metabolic diseases, virology, and ophthalmology. Indaco BIO Lombardia Fund is a 20 million investment fund managed by Indaco Venture SGR S.p.A, selected through a public call for proposals by Regione Lombardia as part of the Regional Program of the European Regional Development Fund/PR ERDF 2021-2027 (action 1.6.2), "Lombardia Venture STEP" call managed by Finlombarda. www.indacosgr.com

About LIFE BioCEEd

LIFE BioCEEd a.s. is an EU-based venture capital entity supporting the development and commercialization of innovative early-stage biomedical and healthcare technologies. Combining investment with hands-on company building, it partners with scientists and founders to move research from the lab towards patients. LIFE BioCEEd is based in Prague, Czech Republic. www.bioceed.eu